Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is so amusing. Thanks Walhall. Never a dull moment.
Isn't it true that people who have conversations with themselves under multiple different identities are exhibiting texbook symptoms of schizophrenic alcoholic dementia?
Perhaps someone with laser-guided insights could comment on this. And perhaps share any insights he/she may also have on how long it takes for schizophrenic alcoholic dementia to progress to end-stage liver disease. Is it also true that progression occurs more rapidly in patients who are of Northern European descent?
And isn't it true that Venturis Therpeutics/CVBT recently filed a patent on treating schizophrenic alcoholic dementia with its drug?
I'm sure we will hear the details of this in the 2021 shareholders meeting which will be held in May 2021 as required by the company's bylaws. Oh wait...there is no shareholders meeting being held in May 2021, in violation of the company's bylaws AND Calvin Wallen's written promises to the shareholders, FOR THE SECOND YEAR IN A ROW.
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465
Any more news on Zhittya Genesis Medicine IPO? If they raised mucho dinero in an IPO that would be bad news for Venturis.
Zhittya Genesis Medicine YouTube videos are pretty impressive. I think we should do that.
Good to see you on the board again, Slalom. I've missed your laser guided posts. As a matter of interest have you heard anything about an influx of cash into our company?
If you don't want to post it you can email me at the usual address.
The new IP is, IMHO, blockbuster stuff.
I understand that the following is referred to as projection.
"This is all of what one would expect from an alleged crook (the Grand Poobah here) and his cronies of idiots from the oil and gas industry, who know about as much about biotech as Kim Kardashian does. At least she has real wealth, and actually earned it honestly. Unlike those who shall not be named who have been accused of theft of company assets, theft of investor assets, and fraud more than once in their careers."
Ya reckon......LOL
Filing a patent, yes it could be complete Dan,Dan the Conman aka Cr@p. Having a patent granted by The United States Patent & Trademark Office is completely different. VT now has 11 different patents on it therapeutic programs & 52 pending.
Remind me, how many patents does Shittya have?
[cue the Jeopardy! tune]
Oh, that's correct, ZERO, Nada, Cero, sifr, Nul, Nula, Kore, ????, Zilch!!
I would not buy into the IPO. I believe Montano will suck in many investors to put himself back into the green. As a longtime CVBT stock owner I am out thousands at this point due largely to Montano's mismanagement.
To Quote JBDC
"LOL!!!!!!
Some posters have a great sense of humor"
I'm laughing hard at the stupidity of Venturis Therapeutics' leadership. I too could create a patent portfolio of nonsense (which is what Venturis has) by filing a patent, for example, that indicates that Martian pixie dust combined with water cures all cancer. Gee, that's an original idea no one has taken before--and I wonder why?
That's what Venturis Therapeutics has done. Filing patents on nonsense that not only is completely unproven, but worse, which no one cares about. If this stuff is so valuable, why do we not see licensing deals, or partnering deals, or investor deals, or anything at all? We all know the answer--because no one credible wants to touch this company or anything it has, both because of the complete lack of credibility of everyone associated with this thing, the credible allegations that these are bad actors, and that more than anything, none of this is serious.
This is all of what one would expect from an alleged crook (the Grand Poobah here) and his cronies of idiots from the oil and gas industry, who know about as much about biotech as Kim Kardashian does. At least she has real wealth, and actually earned it honestly. Unlike those who shall not be named who have been accused of theft of company assets, theft of investor assets, and fraud more than once in their careers.
Zhittya Genesis Medicine / Venturis Patents. Not often do you see the Chief Financial Officer of a company listed as an inventor. May spell trouble if someone wants to challenge.
The interesting thing is that no one outside of the insiders have a clue what molecules VT has, especially the new molecule they now control.
Who will be appointed as the new CEO of Shittya before their upcoming IPO as bankrupts such as Snake Oil Dan can't be CEOs of public entities.
I believe it's the Kiev Tier 3 exchange. They were already turned down by the Lagos Secondary Market.
I agree it's good for Danny Boy that he now only owes VT $1.7 million. If he sold Shiitya to VT that would pay down another $500,000. Where do you think he'll get the other $1.2 million from?
Also, as far as I'm aware bankrupts can't be the CEO of a company going public.
Zhittya Genesis Medicine / Venturis Patents. I saw the post on the new Venturis patent - did not recognize the names of the listed inventors. Are they still with Venturis?
I saw that Zhittya Genesis Medicine was looking into FGF for rheumatoid arthritis. Pretty neat. Venturis should check it out.
What exchange will Zhittya Genesis Medicine shares be listed on? Is this where our former CVBT shares will be listed?
CVBT/VT HAS NOT MADE A SINGLE MOLECULE OF FGF-1 IN THE LAST SEVEN YEARS
Zhittya Genesis Medicine has a new batch of FGF-1 and is now conducting Phase I clinical trials for multiple indications.
CVBT has yet to even produce the FGF-1 molecule. When will CVBT/VT start clinical trials?
Zhittya Genesis Medicine IPO?
Individuals on this board have reported that Zhittya Genesis Medicine may be doing an IPO in the future. What will happen to the value of CVBT shares if that were to happen?
The new administration took control of CVBT in 2014, after 7 years how much progress has our administration made in going public again? Is it possible that Dan Montano's Zhittya Genesis Medicine is passing us to do an IPO?
Zhittya Genesis Medicine IPO?
Individuals on this board have reported that Zhittya Genesis Medicine may be conducting an IPO soon. Is there any verity to this claim? With Zhittya also developing FGF-1 based drugs, how would that affect CVBT's IPO, if it ever happens?
What is CVBT's status on conducting an IPO? Is there a future for CVBT in open trading? How would the recent court case that has resulted in a $1 million dollar judgment against CVBT affect that IPO?
I would love to hear your thoughts, JohnnyMc, on the good news on VT's new heart patent?
LOL!!!!!!
Some posters have a great sense of humor
I remember CVBT'S 2005 IPO when because of Bankrupt Man aka Dani C. Montano's "interesting past exploits" we ended up on the OTCBB. I'm not even sure OTCBB will have him on there nowadays.
I've got a sore stomach laughing so hard at the prospect.
Zhittya Genesis Medicine IPO?
You "...imagine that the IPO is not far out [for Dan Montano's company]...". Since Zhittya Genesis Medicine is also advancing FGF-1 on multiple avenues, do you think Zhittya would be a good biotech IPO? What do you know about Zhittya's IPO???
How would Zhittya Genesis Medicine's IPO affect CVBT?
Yet another patent granted by USPTO for VT's Ischemic Heart Disease therapy.
It is a comprehensive piece of IP which has 15 different claims to it.
Wow, VT is killing it. Their comprehensive patent portfolio sets it aside from the vast majority of biotech companies.
Venturis Therapeutics Inc. Announces Granting of US Patent for the Angiogenic Treatment of Ischemic Heart Disease, issued April 6, 2021, with 15 Patent Claims
As per VT's presentation & the UN WIPO:-
Patents at the Core: the Biotech Business
World Intellectual Property Organisation - WIPO
“Anyone, I would imagine, who has tried
to create a biotech company knows just how important patents are. You learn this when you’re
studying, and again at your first job, and if you haven’t done so before, you realize it the first
time you
meet potential investors.”
Mads Øvlisen, Chairman of the Board of
Directors, Novo Nordisk
LOL!!!
Dan Montano has obviously decided to amongst the top biotech companies in Vegas such as mmm, ahh, mmm,well,mmm.
Yep, seems appropriate.
Good Ol' Dan being in the "hotbed of Life Sciences in Las Vegas"
Montano hasn't moved far from the old CVBT office in Vegas, about 2 blocks away. With all the praises for his new company I imagine the IPO is not far out.
Zhittya Genesis Medicine Announces Further Research
On top of the various other research projects currently being conducted by Zhittya Genesis Medicine, Zhittya has announced research in treating autism using FGF-1.
Zhittya Genesis Medicine appears to be ahead of the research game in countless aspects. Where is CVBT's research and development program? Why have we not heard any news of new research from CVBT/VT despite over 6 years with our new administration?
The 4 billion hits that Shittya has received don't count for diddly squat with the US FDA which of course is the same situations for Phase 1 trials in Mexico.
The VT Phase 2b/3 trials under US FDA auspices have a better ring to it than Phase 1 trials in Mexico.
But Shittya does have 5 billion hits on their YouTube channel. I guess it must be game over. LOL!!!
Zhittya Genesis Medicine Announces Phase I Clinical Trials
Zhittya Genesis Medicine has announced that it has been approved to conduct a Phase I Clinical Trial using FGF-1 to treat ALS. This is in addition to the various clinical activity that Zhittya Genesis Medicine has conducted over the past six years.
How much has CVBT's/VT's clinical trials moved in the last 6 years? There seems to be absolutely no activity in the clinical development department, a principle aspect of any biotechnology company.
DOES CVBT/VT EVEN HAVE FGF-1????????????
Zhittya Genesis Medicine Announces Joint Webinar
Zhittya Genesis Medicine announced a joint hosting webinar on Therapeutic Angiogenesis and FGF-1 with multiple doctors and clinics. Zhittya Genesis Medicine has amassed over a quarter million views on their YouTube videos, tens of thousands of subscribers, and millions of impressions on their online marketing.
What is CVBT doing to get connected with the online community? Are we still mailing out brochures or will we advance into the 21st century? Why does CVBT not have any Social Media? Over 4 billion people worldwide use social media and CVBT/VT has yet to tap into that market.
Zhittya Regenerative Medicine appears to have found a cooperative regulatory authority in Mexico and will get their trials going soon. What patients are being treated now by Venturis?
Let's keep it simple.
Dan Montano owes VT $1.7 million net.
Just to remind you.
In arbitration Danny Boy was awarded $800,000 in back wages. VT has an award c/o Calvin Wallen amounting to $2.5 million netting out to $1.7 million.
I wonder where Danny Boy will come up with that sort of money?
He needs to rip off a lot more senior citizens at the Money Shows to come up with $1.7 million.
Daniel C Montano/Zhittya Genesis Medicine will now reverse the tables and take aim at Venturis and their Directors in the courts. Stay tuned!!
Zhittya Genesis Medicine has its own YouTube channel with many presentations posted. Why not do this for CVBT/Venturis??
Zhittya Genesis Medicine has announced it will begin a new program to used inhaled FGF to reverse lung damage in COVID-19 patients. I noticed Venturis announced patent filings in this area - what work is going on now?
I am absolutely delighted to report that this is not the case.
dan montano was awarded $800,000 in back salary. Unfortunately, for FAILED_CEO, VT via the largess of Calvin Wallen, III holds a $2.5 million damages case which nets out to dan montano owing $1,700,000 to VT. OUCH x $1.7m!!!!!
VERY INTERESTING!!
dan montano was awarded $800,000 in back salary. Unfortunately, VT via the largess of Calvin Wallen, III holds a $2.5 million damages case which nets out to dan montano owing $1,700,000 to VT. OUCH x $1.7m!!!!!
Daniel C Montano and Zhittya Regenerative Medicine headed for victory over Venturis after receiving a favorable ruling from Las Vegas arbitration case!
I've found out that Zhittya Genesis Medicine is developing an intranasal spray for Parkinson's disease. Is Venturis looking at this?
Daniel C Montano with Zhittya Genesis Medicine will be coming to Texas to take a look at Venturis’ financials so I have been informed.
Zhittya Genesis Medicine will seize Venturis assets I have been informed as part of the arbitration award.
Let me help you, CVBT Fan.
Zhittya did NOT win a lawsuit. The failed CEO of Shittya was awarded past wages in an arbitration, not a lawsuit. Unfortunately for FailedCEO, VT has a $2.5 million lawsuit award by the courts in Nevada. FailedCEO's wage award amounted to $800,000. So, bottom line, FailedCEO owes Venturis Therapeutics $1,700,000. Should we have a whip round to see if we can help FailedCEO. I reckon we could raise $10.49 for him. Only $1,699,989.51 to go...........................
History of a FAILED CEO
p.s. Shittya has no IP. VT has a comprehensive Patent Portfolio. Poor ol' FAILED CEO!!
Apart from anything else he hasn't won any cases. He was awarded his back pay of $800,000 in arbitration. Back pay earned when he was destroying VT. Remember his record. 2005 VT (then CVBT) was capitalized at $1.8 billion. In 2012 it was delisted due to Dan Montano's ineptitude at a value of $40 million.
But hey, Shittya has 2 billion followers on YouTube..........LOL.
Talking of YT I found this hilarious video of Dan's "expertise".
Daniel C. Montano, CEO Extraordinaire - LOL
VT 5 laps ahead in a 6 lap race.
"Zhittya Genesis Medicine is CardioVascular Biotherapeutics (Venturis Therapeutics) only competitor in the development of FGF-1. Zhittya Genesis Medicine was founded by the former CEO and founder of CVBT, Dan Montano. Zhittya Genesis Medicine has since soared (into oblivion) to the top since he left CVBT in 2014."
Zhittya isn't a competitor of VT. Zhittya is what is referred to in Las Vegas as, SMOKE & MIRRORS.
"Under the Marketplace Exclusivity, the first company to obtain approval gets an effective monopoly for 10 years. With Zhittya Genesis Medicine (ZGM) indubitably ahead of Venturis Therapeutics by about six years, it is clear who will be the first to monopolize the FGF-1 industry."
Zhittya is stumbling around in a Phase 1 trial in Mexico. They have treated ZERO patients. VT have a Phase 2 CAD trial ongoing & a Phase 2b/3 pivotal trials. In other words VT is around 5 laps ahead in a 6 lap race.
"Zhittya Genesis Medicine and Venturis/CVBT are the only two companies in the race to commercialize FGF-1. Clearly Zhittya Genesis Medicine is far ahead of Venturis in the race as their announcements clearly state that they now have a large batch of FGF-1 at their disposal, have started numerous clinical trials such as in Parkinson's Disease and ALS, have had countless webinars whose social media campaign has touched tens of millions of people, with their subscriber list at tens of thousands."
Countless webinars mean diddly squat with the US FDA. To reiterate VT is around 5 laps ahead in a 6 lap race.
"CVBT/Venturis has now lost Myerson, CVBT has now lost yet another major court battle, Venturis has now lost the majority of their administration. What do we have? There are no experts running Venturis Therapeutics, those experts fled the company after they testified in court that CVBT was lying!"
Again, completely erroneous. Myerson was fired by VT years ago. Refer to the VT presentation where it lists the comprehensive nature of the CVBT team. Anyone who wants the presentation can contact Grant Gordon (my source) at ggordon@venturistherapeutics.com. Needless to say the naysayers have no up to date information on VT as VT has deliberately flown under the RADAR for years which is changing as I write this.
With Daniel C. Montano's $1 million dollar judgement against CVBT/Venturis Therapeutics (WHICH CVBT/VENTURIS HAS NO OFFSET) it is clear that Dan Montano will be coming after Cardiovascular Biotherapeutics.
VT has offset due to Calvin Wallen assigning his $2.5 million judgement against Dan Montano to VT. This means that Dan Montano now owes VT $1.7 million.
Every Cardiovascular Biotherapeutics/Venturis Therapeutics shareholder has to keep up with Zhittya Genesis Medicine because they are our only competition! Our competition is leaving us in the dust, without a doubt they are six years ahead of us!
To reiterate (yet again) VT is around 5 laps ahead in a 6 lap race.
Ultimately I must ask, Zhittya Genesis Medicine has proven that in 6 years a lot of progress can be made. Where is CVBT/Venturis Therapeutics progress? We have made no drug, we have had no shareholders meeting, we have done nothing but lose court battle after court battle in the last half decade. We are losing. When will our CVBT management respond?
VT has drug & are in pivotal trials with the US FDA. Zhittya is in a Phase 1 trial in Mexico, not under FDA auspices.
Every CVBT shareholder should care.
Every VT shareholder does care and are pleased to be on the equivalent of a super yacht as opposed to SS Titanic (Dan Montano/Zhittya).
The one area that Dan Montano is miles ahead of VT & VT management is the number of failed/bankrupted businesses he’s been involved in scuppering. Something in the order of 20 failed businesses over the past 30 years. In addition Dan Montano is in personal bankruptcy. A SERIAL FAILURE.
VT has a comprehensive IP portfolio. Zhittya have nada, not one patent to its name. The failed CEO, Dan Montano, actually believes that in biotechnology IP is worthless. That alone tells you all you need to know about the failed CEO.
Imagine a company so great it's ONLY measure of success is it's record in the courtroom. Most companies I've worked for pride themselves on avoiding litigation. But not Daniel C Montano. Dan seems to welcome it. Because, you know, wasting money on lawyers is a great allocation of resources.
CVBT/VT has lost EVERY lawsuit to Zhittya Genesis Medicine/Zhittya Regenerative Medicine and Daniel C. Montano
Since Dan Montano left the company in 2014 to start Zhittya, our management has consistently attempted to harm the new company. After seven years of lawsuits, all of them have been ruled in favor of Zhittya Genesis as well as their CEO, Dan Montano. The most recent ruling has resulted in a $1 million dollar judgement against CVBT/VT, confirmed by the US Federal Court. This confirmation gives Zhittya and Dan Montano the ability to do a debtors exam in May.
What assets can Dan Montano take in this debtors exam?
Zhittya Genesis Medicine Lawsuit Against CardioVascular BioTherapeutics- victory for Zhittya Genesis Medicine confirmed by the US Federal Court
CVBT/Venturis Therapeutics' claim of IP theft was dismissed in total. Zhittya Genesis Medicine/Zhittya Regenerative Medicine was confirmed to own all of its IP without question. CVBT/VT's management's attempt to harm their competitor has backfired. Dan Montano, CEO of Zhittya Genesis Medicine/Zhittya Regenerative Medicine now has a judgement against CVBT/VT for $1 million dollars confirmed by the United States Federal Courts.
Zhittya Genesis Medicine vindicated by recent court ruling. All the crap about stealing IP from CVBT was bull - CVBT lost 100% of their arguments!
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3648
|
Created
|
04/08/05
|
Type
|
Free
|
Moderators |
VENTURIS THERAPEUTICS (formerly Cardiovascular
Biotherapeutics or CVBT) is a dead, zombie company
that hasn't run a single clinical trial in nearly 15
years. Not even one patient (!) has been treated
since 2007. Venturis Therapeutics is insolvent,
illiquid, and is controlled and run by an individual
who was accused by the U.S government of
embezzling $14 million from his previous company.
Venturis' lawyer, Barry Cannaday of Dentons (one
of the largest law firms in the U.S.), withdrew from
representing Venturis in April 2021 because Dentons
is owed over $200,000 by Venturis, and Mr. Cannaday
attested that "there are currently no assets or
revenue streams" to pay Dentons. Yet anonymous
advocates for Venturis (who I personally believe are
the company's desperate leadership) lie about public
facts that are easily verifiable. One of the most
absurd false claims is that there are (allegedly) two
ongoing pivotal clinical trials (see that particular
false claim below). These "clinical trials" exist only
in cyberspace but not in the real world the rest of us
(including Dentons) live in. That said, enjoy the
entertainment that lies below. Hopefully it gives you
some good laughs - that's about all that's left from
this dead, zombie company. Enjoy!
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS OVERVIEW
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel
therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and
peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction,
infarct stroke, degenerative disk disease and Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on targeted delivery of next generation
molecules which will improve the quality of life for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when administered to ischemic organs and
tissues. These anatomical targets are shown in our pipeline section.
vt.care
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |